CA Patent

CA2777128A1 — Methods and compositions for treating cancer

Assigned to Ariad Pharmaceuticals Inc · Expires 2011-05-05 · 15y expired

What this patent protects

The invention features methods, kits, and pharmaceutical compositions for treating cancer using 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-y1)-methyl)-3-(trifluoromethyl)phenyl)benzamide.

USPTO Abstract

The invention features methods, kits, and pharmaceutical compositions for treating cancer using 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-y1)-methyl)-3-(trifluoromethyl)phenyl)benzamide.

Drugs covered by this patent

ponatinib-hydrochloride (PONATINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CA2777128A1
Jurisdiction: CA
Classification: —
Expires: 2011-05-05
Drug substance claim: No
Drug product claim: No
Assignee: Ariad Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.